Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,696

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Arain, Mustafa A., Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey, Cooper, Harry S., Deming, Dustin, Farkas, Linda, Garrido-Laguna, Ignacio, Grem, Jean L., Gunn, Andrew, Hecht, J. Randolph, Hoffe, Sarah, Hubbard, Joleen, Hunt, Steven, Johung, Kimberly L., Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcahy, Mary F., Nurkin, Steven, Overman, Michael J., Parikh, Aparna, Patel, Hitendra, Pedersen, Katrina, Saltz, Leonard, Schneider, Charles, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Gregory, Kristina M., Gurski, Lisa A.·2021·Journal of the National Comprehensive Cancer Network
DOI 10.6004/jnccn.2021.0012
Open this paper in CoChat — free account

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2021.0012

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 607

  1. Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 · DOI · Paper page
  2. Deenen, 2016, Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis, J Clin Oncol, 34, 227, 10.1200/JCO.2015.63.1325 · DOI · Paper page
  3. Henricks, 2018, DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis, Lancet Oncol, 19, 1459, 10.1016/S1470-2045(18)30686-7 · DOI · Paper page
  4. Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, 14, 1208, 10.1016/S1470-2045(13)70447-9 · DOI · Paper page
  5. 2020, Drug Administration Package Insert STIVARGA regorafenib tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  6. Grothey, 2011, Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7, J Clin Oncol, 29, 421, 10.1200/JCO.2010.31.5911 · DOI · Paper page
  7. Yoo, 2006, Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, Clin Colorectal Cancer, 6, 202, 10.3816/CCC.2006.n.036 · doi:10.3816/ccc.2006.n.036
  8. Kemeny, 2006, Management of liver metastases from colorectal cancer, Oncology (Williston Park), 20, 1161
  9. Masi, 2011, Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis, J Natl Cancer Inst, 103, 21, 10.1093/jnci/djq456 · DOI · Paper page
  10. Artale, 2008, Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer, J Clin Oncol, 26, 4217, 10.1200/JCO.2008.18.7286 · DOI · Paper page
  11. Folprecht, 2016, Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study, Ann Oncol, 27, 1273, 10.1093/annonc/mdw176 · DOI
  12. Seymour, 2007, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet, 370, 143, 10.1016/S0140-6736(07)61087-3 · DOI · Paper page
  13. Rossini, 2020, Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO, Br J Cancer, 124, 183, 10.1038/s41416-020-01089-9 · DOI
  14. Sul, 2016, FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1, Oncologist, 21, 643, 10.1634/theoncologist.2015-0498 · DOI · Paper page
  15. Iwamoto, 2015, FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study, Ann Oncol, 26, 1427, 10.1093/annonc/mdv197 · DOI
  16. Dai, 2013, Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials, Clin Drug Investig, 33, 779, 10.1007/s40261-013-0125-6 · DOI
  17. Cheng, 2011, Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005, Am J Clin Oncol, 34, 573, 10.1097/COC.0b013e3181fe41ed · DOI · Paper page
  18. Cocco, 2019, Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions, Cancer Res, 79, 1047, 10.1158/0008-5472.CAN-18-3126 · DOI · Paper page
  19. LONSURF, 2019, Drug Administration Package Insert trifluridine tipiracil tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  20. Baselga, 2008, Determinants of RASistance to anti-epidermal growth factor receptor agents, J Clin Oncol, 26, 1582, 10.1200/JCO.2007.15.3700 · DOI
  21. Sobrero, 2009, Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer, Oncology, 77, 113, 10.1159/000229787 · DOI
  22. Wang, 2010, KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine, Adv Anat Pathol, 17, 23, 10.1097/PAP.0b013e3181c6962f · DOI
  23. Panitumumab, 2017, Administration Package Insert Vectibix Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food Drug, 17, 207
  24. Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 · DOI · Paper page
  25. Lenz, 2020, Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): two-year clinical update, J Clin Oncol, 38, 4040, 10.1200/JCO.2020.38.15_suppl.4040 · DOI
  26. Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017 · DOI · Paper page
  27. Goldstein, 2015, Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?, Oncologist, 20, 981, 10.1634/theoncologist.2015-0028 · DOI
  28. Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
  29. Moretto, 2016, Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer, Oncologist, 21, 988, 10.1634/theoncologist.2016-0084 · DOI
  30. Stangl, 1994, Factors influencing the natural history of colorectal liver metastases, Lancet, 343, 1405, 10.1016/S0140-6736(94)92529-1 · DOI · Paper page
  31. de Gramont, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 13, 1225, 10.1016/S1470-2045(12)70509-0 · DOI · Paper page
  32. Muratore, 2007, Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?, Ann Surg Oncol, 14, 766, 10.1245/s10434-006-9146-1 · DOI · Paper page
  33. Ikenoue, 2003, Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors, Cancer Res, 63, 8132
  34. Botrel, 2016, Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis, BMC Cancer, 16, 677, 10.1186/s12885-016-2734-y · DOI
  35. Welch, 2010, Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review, Ann Oncol, 21, 1152, 10.1093/annonc/mdp533 · DOI · Paper page
  36. Wang, 2010, KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine, Adv Anat Pathol, 17, 23, 10.1097/PAP.0b013e3181c6962f · DOI
  37. Guo, 2016, XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis, Cancer Invest, 34, 94, 10.3109/07357907.2015.1104689 · DOI
  38. Choti, 2002, Trends in long-term survival following liver resection for hepatic colorectal metastases, Ann Surg, 235, 759, 10.1097/00000658-200206000-00002 · DOI · Paper page
  39. Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
  40. Kopetz, 2019, Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer, N Engl J Med, 381, 1632, 10.1056/NEJMoa1908075 · DOI · Paper page
  41. Hecht, 2015, SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line rreatment in patients with unresectable wild type KRAS metastatic colorectal cancer, Clin Colorectal Cancer, 14, 72, 10.1016/j.clcc.2014.12.009 · DOI
  42. Bendell, 2015, Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer, Cancer Chemother Pharmacol, 76, 925, 10.1007/s00280-015-2850-4 · DOI
  43. Guo, 2016, XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis, Cancer Invest, 34, 94, 10.3109/07357907.2015.1104689 · DOI
  44. Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855 · DOI · Paper page
  45. Obermannová, 2016, Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression, Ann Oncol, 27, 2082, 10.1093/annonc/mdw402 · DOI
  46. Elias, 2005, Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect, Ann Surg Oncol, 12, 900, 10.1245/ASO.2005.01.010 · DOI · Paper page
  47. Saridaki, 2010, BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome, Br J Cancer, 102, 1762, 10.1038/sj.bjc.6605694 · DOI
  48. Masi, 2015, Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial, Ann Oncol, 26, 724, 10.1093/annonc/mdv012 · DOI · Paper page
  49. Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 · DOI · Paper page
  50. Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069 · DOI · Paper page
  51. Deenen, 2016, Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis, J Clin Oncol, 34, 227, 10.1200/JCO.2015.63.1325 · DOI · Paper page
  52. Loupakis, 2015, Primary tumor location as a prognostic factor in metastatic colorectal cancer, J Natl Cancer Inst, 107, 107, 10.1093/jnci/dju427 · DOI · Paper page
  53. Seymour, 2012, Conceptual approaches to metastatic disease, Ann Oncol, 23, x77, 10.1093/annonc/mds361 · doi:10.1093/annonc/mds361
  54. Nishino, 2016, Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer, Cancer Immunol Res, 4, 289, 10.1158/2326-6066.CIR-15-0267 · DOI
  55. Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
  56. Bekaii-Saab, 2019, Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study, Lancet Oncol, 20, 1070, 10.1016/S1470-2045(19)30272-4 · DOI · Paper page
  57. Santini, 2010, High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice, Ann Oncol, 21, 1565, 10.1093/annonc/mdq318 · DOI
  58. Meulendijks, 2015, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 16, 1639, 10.1016/S1470-2045(15)00286-7 · DOI · Paper page
  59. Mauri, 2019, Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies, Cancer Treat Rev, 73, 41, 10.1016/j.ctrv.2018.12.006 · DOI
  60. Petrelli, 2012, Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials, Ann Oncol, 23, 1672, 10.1093/annonc/mdr592 · DOI
  61. Buchler, 2014, Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis, BMC Cancer, 14, 323, 10.1186/1471-2407-14-323 · doi:10.1186/1471-2407-14-323
  62. Safaee Ardekani, 2012, The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis, PLoS One, 7, e47054, 10.1371/journal.pone.0047054 · DOI · Paper page
  63. Monzon, 2009, The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer, Arch Pathol Lab Med, 133, 1600, 10.5858/133.10.1600 · DOI
  64. Price, 2011, Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer, J Clin Oncol, 29, 2675, 10.1200/JCO.2010.34.5520 · DOI · Paper page
  65. Hurwitz, 2012, Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?, J Clin Oncol, 30, 580, 10.1200/JCO.2011.40.7031 · DOI
  66. Seymour, 2007, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet, 370, 143, 10.1016/S0140-6736(07)61087-3 · DOI · Paper page
  67. 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  68. Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 · DOI · Paper page
  69. Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 26, 13, 10.1093/annonc/mdu378 · DOI · Paper page
  70. Liu, 2014, Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians, Pharmacogenomics J, 14, 120, 10.1038/tpj.2013.10 · DOI
  71. Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, 14, 1208, 10.1016/S1470-2045(13)70447-9 · DOI · Paper page
  72. Reddy, 2008, Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases, J Am Coll Surg, 206, 96, 10.1016/j.jamcollsurg.2007.06.290 · DOI
  73. Petrelli, 2013, The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials, Target Oncol, 8, 173, 10.1007/s11523-013-0257-x · DOI
  74. Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 · DOI · Paper page
  75. Shankaran, 2018, Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States, Am J Clin Oncol, 41, 65, 10.1097/COC.0000000000000231 · DOI
  76. Dai, 2013, Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials, Clin Drug Investig, 33, 779, 10.1007/s40261-013-0125-6 · DOI
  77. Bailey, 2014, Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010, JAMA Surg, 32, 1
  78. Mattison, 2002, Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics, Pharmacogenomics, 3, 485, 10.1517/14622416.3.4.485 · DOI
  79. Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 · DOI · Paper page
  80. Hochster, 2014, Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT, Ann Oncol, 25, 1172, 10.1093/annonc/mdu107 · DOI
  81. Sepulveda, 2017, Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology, J Mol Diagn, 19, 187, 10.1016/j.jmoldx.2016.11.001 · DOI
  82. Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 · DOI · Paper page
  83. Graham, 2018, A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US, J Med Econ, 21, 1075, 10.1080/13696998.2018.1510409 · DOI
  84. Chibaudel, 2009, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study, J Clin Oncol, 27, 5727, 10.1200/JCO.2009.23.4344 · DOI · Paper page
  85. Foster, 1984, Treatment of metastatic disease of the liver: a skeptic’s view, Semin Liver Dis, 4, 170, 10.1055/s-2008-1040656 · doi:10.1055/s-2008-1040656
  86. Zhang, 2013, Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis, J Chemother, 25, 170, 10.1179/1973947813Y.0000000070 · DOI
  87. Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 · DOI · Paper page
  88. Chibaudel, 2009, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study, J Clin Oncol, 27, 5727, 10.1200/JCO.2009.23.4344 · DOI · Paper page
  89. Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
  90. Burtness, 2009, NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer, J Natl Compr Canc Netw, 7, S5, 10.6004/jnccn.2009.0074 · DOI
  91. Lenz, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): clinical update, J Clin Oncol, 37, 3521, 10.1200/JCO.2019.37.15_suppl.3521 · DOI
  92. Hochster, 2007, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol, 25, 4028, 10.1200/JCO.2007.13.5251 · doi:10.1200/jco.2007.13.5251
  93. Brulé, 2015, Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17, Eur J Cancer, 51, 1405, 10.1016/j.ejca.2015.03.015 · DOI · Paper page
  94. Colucci, 2005, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale, J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113 · DOI · Paper page
  95. Hofheinz, Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials [published online August 30, 2016], Gastroenterol Res Pract
  96. Porschen, 2007, Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group, J Clin Oncol, 25, 4217, 10.1200/JCO.2006.09.2684 · DOI · Paper page
  97. Hurwitz, 2011, Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies, J Clin Oncol, 29, 1757, 10.1200/JCO.2010.32.3220 · DOI · Paper page
  98. Valtorta, 2015, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Mod Pathol, 28, 1481, 10.1038/modpathol.2015.98 · DOI · Paper page
  99. Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 · DOI · Paper page
  100. Schmoll, 2017, “CHARTA”: FOLFOX/bevacizumab vs FOLFOXIRI/bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO, J Clin Oncol, 35, 3533, 10.1200/JCO.2017.35.15_suppl.3533 · doi:10.1200/jco.2017.35.15_suppl.3533
  101. Muratore, 2007, Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?, Ann Surg Oncol, 14, 766, 10.1245/s10434-006-9146-1 · DOI · Paper page
  102. OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
  103. Peeters, 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J Clin Oncol, 28, 4706, 10.1200/JCO.2009.27.6055 · DOI · Paper page
  104. Hoff, 2004, Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma, J Clin Oncol, 22, 2078, 10.1200/JCO.2004.05.072 · doi:10.1200/jco.2004.05.072
  105. Berlin, 2020, Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer, J Clin Oncol, 38, 824, 10.1200/JCO.2020.38.4_suppl.824 · doi:10.1200/jco.2020.38.4_suppl.824
  106. Schirripa, 2015, Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer, Ann Oncol, 26, 2503, 10.1093/annonc/mdv385 · DOI
  107. OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
  108. Kidwell, 2012, Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 118, 5614, 10.1002/cncr.27593 · DOI
  109. Cao, 2009, A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer, Int J Colorectal Dis, 24, 677, 10.1007/s00384-009-0655-9 · DOI
  110. Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867 · DOI · Paper page
  111. Hainsworth, 2018, Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study, J Clin Oncol, 36, 536, 10.1200/JCO.2017.75.3780 · DOI · Paper page
  112. Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 · DOI · Paper page
  113. Cunningham, 2013, Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, Lancet Oncol, 14, 1077, 10.1016/S1470-2045(13)70154-2 · DOI · Paper page
  114. Knijn, 2011, The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients, Eur J Cancer, 47, 369, 10.1016/j.ejca.2010.10.006 · doi:10.1016/j.ejca.2010.10.006
  115. 2020, Drug Administration Package Insert KEYTRUDA pembrolizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 088
  116. Van Cutsem, 2018, The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer, Eur J Cancer, 90, 63, 10.1016/j.ejca.2017.10.009 · DOI
  117. Grothey, 2004, Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment, J Clin Oncol, 22, 1209, 10.1200/JCO.2004.11.037 · DOI · Paper page
  118. Cannistra, 2007, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer, J Clin Oncol, 25, 5180, 10.1200/JCO.2007.12.0782 · DOI · Paper page
  119. Cassidy, 2011, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 · DOI · Paper page
  120. Miles, 2011, Reply to P. Potemski, J Clin Oncol, 29, e386, 10.1200/JCO.2010.34.1479 · doi:10.1200/jco.2010.34.1479
  121. Segelov, 2014, The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials, Br J Cancer, 111, 1122, 10.1038/bjc.2014.404 · DOI
  122. VenookAP, 2016, Impact of primary tumor location on overall survival OS and progression free survival PFS in patients pts with metastatic colorectal cancer mCRC of all RAS wt patients on CALGB Alliance abstract Congress https org, Analysis, 1
  123. Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164, J Clin Oncol, 38, 11, 10.1200/JCO.19.02107 · DOI · Paper page
  124. Innocenti, 2004, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan, J Clin Oncol, 22, 1382, 10.1200/JCO.2004.07.173 · DOI · Paper page
  125. Besora, 2018, Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients, J Cancer Res Clin Oncol, 144, 1793, 10.1007/s00432-018-2691-8 · doi:10.1007/s00432-018-2691-8
  126. Sartore-Bianchi, 2019, HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer, Oncologist, 24, 1395, 10.1634/theoncologist.2018-0785 · DOI · Paper page
  127. Grothey, 2014, Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study, Pharmacoepidemiol Drug Saf, 23, 726, 10.1002/pds.3633 · DOI
  128. Wen, 2013, Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis, Ann Oncol, 24, 171, 10.1093/annonc/mds211 · DOI
  129. Petrelli, 2013, FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, 12, 145, 10.1016/j.clcc.2013.04.006 · DOI
  130. Haller, 2008, Potential regional differences for the tolerability profiles of fluoropyrimidines, J Clin Oncol, 26, 2118, 10.1200/JCO.2007.15.2090 · DOI · Paper page
  131. Sinicrope, 2017, Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: A secondary analysis of 2 randomized clinical trials, JAMA Oncol, 3, 472, 10.1001/jamaoncol.2016.5469 · DOI
  132. Kopetz, 2020, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]., J Clin Oncol, 35, JCO2001994
  133. Köhne, 2012, First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer, J Cancer Res Clin Oncol, 138, 65, 10.1007/s00432-011-1061-6 · DOI
  134. Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855 · DOI · Paper page
  135. Schmoll, 2006, Update on capecitabine in colorectal cancer, Oncologist, 11, 1003, 10.1634/theoncologist.11-9-1003 · DOI
  136. Yaeger, 2018, Clinical sequencing defines the genomic landscape of metastatic colorectal cancer, Cancer Cell, 33, 125, 10.1016/j.ccell.2017.12.004 · DOI · Paper page
  137. Cassidy, 2008, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer, J Clin Oncol, 26, 2006, 10.1200/JCO.2007.14.9898 · DOI · Paper page
  138. Graham, 2018, A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US, J Med Econ, 21, 1075, 10.1080/13696998.2018.1510409 · DOI
  139. Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164, J Clin Oncol, 38, 11, 10.1200/JCO.19.02107 · DOI · Paper page
  140. Cassidy, 2008, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer, J Clin Oncol, 26, 2006, 10.1200/JCO.2007.14.9898 · DOI · Paper page
  141. Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5 · doi:10.1245/s10434-006-9215-5
  142. Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 · DOI · Paper page
  143. Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 · DOI · Paper page
  144. Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 26, 13, 10.1093/annonc/mdu378 · DOI · Paper page
  145. Gatalica, 2019, Molecular characterization of cancers with NTRK gene fusions, Mod Pathol, 32, 147, 10.1038/s41379-018-0118-3 · DOI · Paper page
  146. Lièvre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, 26, 374, 10.1200/JCO.2007.12.5906 · DOI · Paper page
  147. CYRAMZA, 2020, Drug Administration Package Insert ramucirumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 037
  148. Tol, 2009, BRAF mutation in metastatic colorectal cancer, N Engl J Med, 361, 98, 10.1056/NEJMc0904160 · DOI · Paper page
  149. Yalcin, 2013, Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results--a Turkish Oncology Group Trial, Oncology, 85, 328, 10.1159/000355914 · DOI
  150. Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
  151. Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 29, 2011, 10.1200/JCO.2010.33.5091 · DOI · Paper page
  152. Gamelin, 2004, Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer, Clin Cancer Res, 10, 4055, 10.1158/1078-0432.CCR-03-0666 · DOI
  153. Hayashi, 2010, Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis, BMC Surg, 10, 27, 10.1186/1471-2482-10-27 · DOI
  154. Ducreux, 2011, Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer, Int J Cancer, 128, 682, 10.1002/ijc.25369 · DOI · Paper page
  155. Kopetz, 2020, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]., J Clin Oncol, 35, JCO2001994
  156. 2019, Drug Administration Package Insert TRAZIMERATM trastuzumab qyyp for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  157. Adenis, 2016, Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program, BMC Cancer, 16, 412, 10.1186/s12885-016-2440-9 · DOI
  158. Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
  159. Ducreux, 2019, Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study, Eur J Cancer, 123, 146, 10.1016/j.ejca.2019.09.015 · DOI
  160. Pietrantonio, 2015, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis, Eur J Cancer, 51, 587, 10.1016/j.ejca.2015.01.054 · DOI · Paper page
  161. Miles, 2011, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials, J Clin Oncol, 29, 83, 10.1200/JCO.2010.30.2794 · DOI
  162. Lee, 2007, Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival, Int J Colorectal Dis, 22, 699, 10.1007/s00384-006-0218-2 · doi:10.1007/s00384-006-0218-2
  163. Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 · DOI · Paper page
  164. Wulaningsih, 2016, Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer, Cochrane Database Syst Rev, 2, CD008593
  165. Berry, 2015, Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis, Ann Oncol, 26, 477, 10.1093/annonc/mdu272 · DOI
  166. Loprinzi, 2014, Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance), J Clin Oncol, 32, 997, 10.1200/JCO.2013.52.0536 · doi:10.1200/jco.2013.52.0536
  167. Innocenti, 2014, Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer, J Clin Oncol, 32, 2328, 10.1200/JCO.2014.55.2307 · DOI
  168. Qu, 2015, Value of bevacizumab in treatment of colorectal cancer: A meta-analysis, World J Gastroenterol, 21, 5072, 10.3748/wjg.v21.i16.5072 · DOI
  169. Cremolini, 2020, Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer, J Clin Oncol, 38, 3314, 10.1200/JCO.20.01225 · DOI · Paper page
  170. Yahagi, 2016, The worse prognosis of right-sided compared with left-sided colon cancers: A systematic review and meta-analysis, J Gastrointest Surg, 20, 648, 10.1007/s11605-015-3026-6 · DOI · Paper page
  171. Costa, 2017, REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study, Clin Colorectal Cancer, 16, 316, 10.1016/j.clcc.2017.03.002 · DOI
  172. Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
  173. Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867 · DOI · Paper page
  174. Miles, 2011, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials, J Clin Oncol, 29, 83, 10.1200/JCO.2010.30.2794 · DOI
  175. Innocenti, 2014, Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer, J Clin Oncol, 32, 2328, 10.1200/JCO.2014.55.2307 · DOI
  176. Tabernero, 2014, Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial, Eur J Cancer, 50, 320, 10.1016/j.ejca.2013.09.013 · DOI · Paper page
  177. Fourrier-Réglat, 2014, Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort, Target Oncol, 9, 311, 10.1007/s11523-013-0296-3 · DOI
  178. Van Cutsem, 2012, Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study, J Clin Oncol, 30, 2861, 10.1200/JCO.2011.40.9243 · DOI
  179. Macedo, 2012, Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups, BMC Cancer, 12, 89, 10.1186/1471-2407-12-89 · DOI
  180. Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
  181. Koopman, 2007, Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, Lancet, 370, 135, 10.1016/S0140-6736(07)61086-1 · DOI · Paper page
  182. Kim, 2016, A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer, Br J Cancer, 115, 1206, 10.1038/bjc.2016.309 · DOI
  183. Van Cutsem, 2001, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097 · DOI · Paper page
  184. Henricks, 2019, A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy, Eur J Cancer, 107, 60, 10.1016/j.ejca.2018.11.010 · DOI
  185. Riesco-Martínez, 2016, Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer, J Oncol Pract, 12, e710, 10.1200/JOP.2015.008730 · DOI
  186. De Roock, 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, 1812, 10.1001/jama.2010.1535 · DOI · Paper page
  187. Wu, 2012, Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis, Eur J Cancer, 48, 1791, 10.1016/j.ejca.2012.03.018 · DOI
  188. Berry, 2015, Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis, Ann Oncol, 26, 477, 10.1093/annonc/mdu272 · DOI
  189. Kidwell, 2012, Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 118, 5614, 10.1002/cncr.27593 · DOI
  190. Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
  191. Lenz, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): clinical update, J Clin Oncol, 37, 3521, 10.1200/JCO.2019.37.15_suppl.3521 · DOI
  192. Gupta, 2020, Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study [abstract], J Clin Oncol, 38, 132, 10.1200/JCO.2020.38.4_suppl.132 · DOI · Paper page
  193. 2019, Drug Administration Package Insert ONTRUZANT trastuzumab dttb for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  194. Gamelin, 2008, Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy, J Clin Oncol, 26, 1188, 10.1200/JCO.2007.15.3767 · doi:10.1200/jco.2007.15.3767
  195. Erbitux, 2020, Drug Administration Package Insert cetuximab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 275
  196. Yamazaki, 2016, Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G), Ann Oncol, 27, 1539, 10.1093/annonc/mdw206 · DOI · Paper page
  197. Costa, 2017, REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study, Clin Colorectal Cancer, 16, 316, 10.1016/j.clcc.2017.03.002 · DOI
  198. 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  199. Zhang, 2012, Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials, Oncol Lett, 3, 831
  200. Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 · DOI · Paper page

200 of 607 shown

Cited by

See all 1,696

Metadata

Authors
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Gregory, K. M., & Gurski, L. A.
Venue
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Published
2021-03
Volume
19
Issue
3
Pages
329-359
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
DOI
10.6004/jnccn.2021.0012
OpenAlex
W3134887329
Cited by
1,696
References
56
FWCI
103.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. https://app.cochat.ai/papers/10.6004/jnccn.2021.0012
The paper
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., . . . Gurski, L. A. (2021). Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2021.0012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.